The drug comes at a time when antibiotic resistance worries are high. Here’s why it matters.
Barbara Hesselgrave
Advertisement
Articles by Barbara Hesselgrave
A cure and a bargain?
Advertisement
Latest Updated Articles
Zolgensma: The $2.1 Million DrugAugust 26th 2019
Lefamulin Could Be Vital in the Pneumonia FightOctober 11th 2019
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Data
2
Conflicting Measles Reports Perpetuate as Cases Continue to Rise
3
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
4
PPV23 Vaccination Found to Not Reduce Cardiovascular Risk
5